Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases

Maslow, Joel N.

doi:10.1080/21645515.2019.1661209

Cited by 11 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A clinical path to successful deployment of an onchocerciasis vaccine has to take into consideration 'need, availability and cost' [126]. This breaks down into numerous factors that must be considered: The desired indication, the final target population, deployment conditions of the product, route of administration, and duration of the protective response.…”

Section: Clinical Trial Criteriamentioning

confidence: 99%

Development of a recombinant vaccine against human onchocerciasis

Abraham

Graham-Brown

Carter

et al. 2021

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Human onchocerciasis caused by the filarial nematode parasite Onchocerca volvulus remains a major cause of debilitating disease infecting millions primarily in Sub-Saharan Africa. The development of a prophylactic vaccine, along with mass drug administration, would facilitate meeting the goal of onchocerciasis elimination by 2030. Areas covered: Models used to study immunity to Onchocerca include natural infection of cattle with Onchocerca ochengi and O. volvulus infective third-stage larvae implanted within diffusion chambers in mice. A vaccine, comprised of two adjuvanted recombinant antigens, induced protective immunity in genetically diverse mice suggesting that it will function similarly in diverse human populations. These antigens were recognized by immune humans and also induced protective immunity against Brugia malayi. We describe the development of a fusion protein composed of the two vaccine antigens with the plan to test the vaccine in cows and non-human primates as a prelude to the initiation of phase 1 clinical trials. Expert opinion: The adjuvanted O. volvulus vaccine composed of two antigens Ov-103 and Ov-RAL-2 was shown to be consistently effective at inducing protective immunity using multiple immune mechanisms. The vaccine is ready for further evaluation in other animal models before moving to clinical trials in humans.

show abstract

Section: Clinical Trial Criteriamentioning

confidence: 99%

Development of a recombinant vaccine against human onchocerciasis

Abraham

Graham-Brown

Carter

et al. 2021

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…11 However, to date there is no clear understanding of where innovators perceive the largest market opportunities to lie. 12 Moreover, lack of a clear overview of vaccines and technologies in development hampers new innovators to join in a concerted effort to realize solutions to public health unmet needs.…”

Section: Introductionmentioning

confidence: 99%

Identifying the gaps in human and veterinary chlamydia vaccine development

et al. 2020

View full text Add to dashboard Cite

Background: Chlamydia infections in humans and animals pose a significant burden on health systems worldwide. While widespread screening, adequate treatment, and prevention programs are helpful to increase awareness and improve screening rates, infection rates are rising. A vaccine is necessary to slow increasing rates, manage negative consequences, and prevent possible antibiotic resistance. We present the current landscape regarding the innovations for commercial vaccine development in a “one-health” context.Methods: We developed a unique dataset containing data of patent documents intended for human and veterinary use, and clinical trials in order to provide a detailed description of the global chlamydia vaccine developments.Results: Analysis of patents and clinical trials intended for human use presented a vaccine field that is underdeveloped, with no commercial human chlamydia vaccine available, and two potential candidates in a phase 1 clinical trial. Comparing innovations concerning chlamydia vaccine developments for both human and veterinary patents, it was clear that these fields are very different and independent of each other. The field is small, and certain companies and researchers show repeated interest. Partnerships among applicants and those involved in chlamydia vaccine innovation would be an important step to take towards innovating and developing an effective vaccine.Conclusions: We have shown that North America is considered, by patent application, to hold the most potential for a chlamydia vaccine, specifically against the Chlamydia trachomatis strain. A new vaccine is likely to be a subunit vaccine with components of the major outer membrane protein antigen.

show abstract

“…In January 2023, according to the list of NTD provided by the World Health Organization (WHO), only Dengue virus (DENV) and chikungunya virus (CHIKV) can be highlighted as single positive-sense RNA ones (Table 1) (Desiree LaBeaud, 2008;Martins-Melo et al, 2018). Nevertheless, many other viruses could be tracked in the category of NTD, as reviewed previously (Maslow, 2019), thus highlighting the importance of these viruses to provide a comprehensive overview of NTD. A summary of the emergence and re-emergence of RNA viruses in the 21st century is listed in Table 1.…”

Section: Emergence and Re-emergence Of Rna Viruses In The 21st Centurymentioning

confidence: 99%

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Rosa-Nunes,

Lucchi,

Andreata-Santos

et al. 2023

Front. Drug Discov.

View full text Add to dashboard Cite

In the 21st Century, emergence and re-emergence of infectious diseases is significant and has an increasing importance in global concern of public health. Based on the COVID-19 pandemic and recently reported epidemics, most human pathogens originate in zoonosis. Many of such pathogens are related to viruses that have RNA genomes, which can be presented structurally as a single-strand or double-strand. During the last two decades, a timeline of major RNA viruses emergencies can be exemplified, such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003, influenza A virus (H1N1) pdm09 in 2009, Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, Ebola virus (EBOV) in 2013–2016, Zika virus (ZIKV) in 2015 and the SARS-CoV-2 pdm19 in 2019. Even so, prophylactic or therapeutic drugs are unavailable for many RNA viruses circulating. Nonetheless, the COVID-19 pandemic brought considerable scientific advances in accelerating progress regarding prophylaxis, antiviral and drug development, and novel treatments. Regarding RNA virus diseases for humans, arboviruses play an essential and neglected role, constantly reemerging and affecting almost half of the human population, for which no drug has been licensed. Here we review the consolidated RNA viruses’ emergence and re-emergence in the 21st Century through available data. Then, we explored valuable lessons gained during the SARS-CoV-2 pandemic and focused on potential epidemiologic updates, prophylaxis, available treatments, and viral drug inhibitors. Finally, we explore arbovirus’s significance and the ongoing development of effective vaccines, antiviral drugs, and novel therapeutic approaches as strategies to control these neglected tropical diseases (NTD).

show abstract

Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases

Cited by 11 publications

References 30 publications

Development of a recombinant vaccine against human onchocerciasis

Development of a recombinant vaccine against human onchocerciasis

Identifying the gaps in human and veterinary chlamydia vaccine development

Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses

Contact Info

Product

Resources

About